Table 2.
Existing indications | Characteristics | Side effects | Usage models | References | |
Candesartan | Hypertension Heart failure |
Angiotensin II receptor antagonist | Birth defects Low blood pressure High blood potassium |
EAAC1 KO mouse | 21 |
Valproic acid | Epilepsy Migraines Bipolar disorder |
Histone deacetylase inhibitor | Birth defects Liver dysfunction Thrombocytopaenia |
GLAST KO mouse NMDA injection |
22 28 |
Geranylgeranyl acetone | Gastric ulcers | Antioxidant Hsp70 inducer |
Liver dysfunction Jaundice |
GLAST KO mouse | 70 |
Edaravone | Acute stroke ALS |
Free radical scavenger | Acute renal failure Liver dysfunction |
EAAC1 KO mouse Optic nerve injury |
23 77 |
Nicotinamide | Pellagra High cholesterol Skin diseases |
Vitamin B3 antioxidant and antipruritic |
Skin flushing Low blood pressure Hyperglycaemia Liver dysfunction |
DBA/2J mouse | 24 |
Amlexanox | Aphthous ulcers Bronchial asthma Allergic rhinitis |
Antiallergic immunomodulator and TBK1 inhibitor | Skin rash Headache Nausea Diarrhoea Liver dysfunction |
Optineurin E50K knock-in mouse | 49 |
ALS, amyotrophic lateral sclerosis; EAAC1, excitatory amino acid carrier 1; GLAST, glutamate/aspartate transporter; Hsp70, heat shock protein 70; KO, knockout; NMDA, N-methyl-D-aspartate; TBK1, TANK-binding kinase 1.